---
title: "Ethos Tech | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286561777.md"
datetime: "2026-05-15T12:04:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286561777.md)
  - [en](https://longbridge.com/en/news/286561777.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286561777.md)
---

# Ethos Tech | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0, missing the estimate of USD 145.02 M.

EPS: As of FY2026 Q1, the actual value is USD -0.11, beating the estimate of USD -2.6542.

#### Cash & Investment Position

As of March 31, 2026, Ethos Technologies Inc. reported cash, cash equivalents, restricted cash, and available-for-sale investments of $68.3 million, a decrease from $80.9 million as of December 31, 2025.

#### Research and Development Expenses

Research and development expenses for the first quarter of 2026 were $7.3 million, down from $11.8 million for the first quarter of 2025.

#### General and Administrative Expenses

General and administrative expenses for the first quarter of 2026 were $4.1 million, compared to $3.9 million for the first quarter of 2025.

#### Total Operating Expenses

Total operating expenses were $11.4 million for the first quarter of 2026, a reduction from $15.7 million for the first quarter of 2025.

#### Loss from Operations

Ethos Technologies Inc. recorded a loss from operations of - $11.4 million for the first quarter of 2026, an improvement from a loss of - $15.7 million for the first quarter of 2025.

#### Total Other Income (Expense), Net

Total other income (expense), net, was $0.6 million for the first quarter of 2026, compared to $0.9 million for the first quarter of 2025.

#### Consolidated Net Loss

The consolidated net loss for the first quarter of 2026 was - $10.7 million, an improvement from - $14.8 million for the first quarter of 2025.

#### Net Loss Attributable to Ethos Technologies Inc.

Net loss attributable to Ethos Technologies Inc. was - $10.7 million for the first quarter of 2026, compared to - $14.8 million for the first quarter of 2025.

#### Total Assets

Total assets amounted to $79.6 million as of March 31, 2026, down from $93.0 million as of December 31, 2025.

#### Total Stockholders’ Equity

Total stockholders’ equity was $57.7 million as of March 31, 2026, decreasing from $67.2 million as of December 31, 2025.

#### Outlook / Guidance

Ethos Technologies Inc. plans to submit an Investigational New Drug (IND) application in June 2026 for a new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis. The company is on track to complete enrollment in the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026. This Phase 3 trial is expected to be a global, randomized, double-blind, placebo-controlled study intending to enroll up to approximately 372 patients.

### Related Stocks

- [LIFE.US](https://longbridge.com/en/quote/LIFE.US.md)

## Related News & Research

- [PowerFleet Q4 2026 Earnings Preview](https://longbridge.com/en/news/289616465.md)
- [ABB  Ltd: ABB share buybacks - June 4, 2026 – June 10, 2026](https://longbridge.com/en/news/289436946.md)
- [Soybean Analysis: 2026 Market Volatility and Trend](https://longbridge.com/en/news/289444628.md)
- [Zedge Q3 2026 Earnings Preview](https://longbridge.com/en/news/289381005.md)
- [Factorial Files Super 8-K Containing Q1 2026 Financial Results | FAC Stock News](https://longbridge.com/en/news/289602927.md)